# (Z)-RG-13022

| | |
|---|---|
| **Cat. No.:** | HY-117523 |
| **CAS No.:** | 149286-90-8 |
| **Molecular Formula:** | $C_{16}H_{14}N_2O_2$ |
| **Molecular Weight:** | 266.29 |
| **Target:** | EGFR |
| **Pathway:** | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | (Z)-RG-13022 is a tyrosine kinase (TK) inhibitor, which inhibits preferentially the TK activity of the EGF receptor and inhibits EGF-stimulated growth of cultured cells. (Z)-RG-13022 exerts an $IC_{50}$ of 11 μM for DNA synthesis in the HN5 cells, which is 3 times more potent than (E)-RG-13022 ($IC_{50}$=38 μM). (Z)-RG-13022 can be used for research of breast cancer cells[1][2]. |
| **In Vitro** | (Z)-RG-13022 (1-100 μM, 24 h) inhibits the DNA synthesis in the HN5 cells dose-dependently and doesn't affect the cell viability[2].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Reddy KB, et al. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 1;52(13):3636-41.

[2]. McLeod HL, et al. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 1996 Dec;74(11):1714-8.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA